MA45430A - Analogues de célastrol - Google Patents

Analogues de célastrol

Info

Publication number
MA45430A
MA45430A MA045430A MA45430A MA45430A MA 45430 A MA45430 A MA 45430A MA 045430 A MA045430 A MA 045430A MA 45430 A MA45430 A MA 45430A MA 45430 A MA45430 A MA 45430A
Authority
MA
Morocco
Prior art keywords
celastrol
analogues
celastrol analogues
Prior art date
Application number
MA045430A
Other languages
English (en)
French (fr)
Inventor
Yanbing Ding
Ralph Mazitschek
Kaisheng Shen
Original Assignee
Erx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erx Pharmaceuticals Inc filed Critical Erx Pharmaceuticals Inc
Publication of MA45430A publication Critical patent/MA45430A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal (AREA)
  • Steroid Compounds (AREA)
  • Optical Filters (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA045430A 2015-10-23 2016-10-21 Analogues de célastrol MA45430A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562245356P 2015-10-23 2015-10-23

Publications (1)

Publication Number Publication Date
MA45430A true MA45430A (fr) 2019-05-01

Family

ID=58558149

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045430A MA45430A (fr) 2015-10-23 2016-10-21 Analogues de célastrol

Country Status (8)

Country Link
US (3) US10662218B2 (enExample)
EP (1) EP3364956A4 (enExample)
JP (3) JP7034078B2 (enExample)
CN (2) CN119241632A (enExample)
AU (3) AU2016342375B2 (enExample)
BR (1) BR112018008103A2 (enExample)
MA (1) MA45430A (enExample)
WO (1) WO2017070615A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7034078B2 (ja) * 2015-10-23 2022-03-11 イーアールエックス ファーマシューティカルズ インコーポレイテッド セラストロールの類似体
AU2017250778B2 (en) 2016-04-15 2021-09-23 Beckman Coulter, Inc. Photoactive macromolecules and uses thereof
DK3471733T3 (da) 2016-06-15 2024-10-14 Targa Biomedical Inc Reagenser, sammensætninger og fremgangsmåder til forbedring af cellers, vævs og organers levedygtighed og funktion
CN108026142B (zh) * 2016-07-04 2022-07-08 艾凯奇(厦门)生物科技有限公司 孤儿核受体Nur77的配体及其用途
CN109705187B (zh) * 2019-01-29 2021-08-20 石家庄学院 一种雷公藤红素衍生物及其制备方法与应用
CN112094313B (zh) * 2019-06-17 2023-07-04 中国科学院上海药物研究所 一类氨基取代的雷公藤红素衍生物以及其制备方法和用途
CN112110977B (zh) * 2019-06-21 2022-02-25 中国科学院上海药物研究所 一类雷公藤红素衍生物、其制备方法及用途
US12441722B2 (en) 2020-01-15 2025-10-14 University Of Florida Research Foundation, Incorporated Therapeutic agents and methods of treatment
CN111202737B (zh) * 2020-03-20 2022-08-05 中国药科大学 雷公藤红素酰胺衍生物在制备治疗自身性免疫疾病药物的应用
WO2022072094A2 (en) * 2020-08-28 2022-04-07 University Of Florida Research Foundation, Incorporated Modulators of nuclear receptor subfamily 4 group a member 1 (nr4a1) and uses thereof
CN115677812B (zh) * 2022-01-18 2023-12-15 聊城大学 一类雷公藤红素衍生物及其制备方法与应用
WO2023249354A1 (ko) * 2022-06-21 2023-12-28 서울대학교산학협력단 디메틸제일아스테럴을 포함하는 근육 감소로 인한 질환 예방 또는 치료용 약학 조성물
EP4554955A1 (en) * 2022-07-15 2025-05-21 Celloram, Inc. Celastrol derivatives
WO2024108035A1 (en) * 2022-11-17 2024-05-23 Erx Pharmaceuticals, Inc Compositions and methods for treatment of prader-willi syndrome
EP4618998A1 (en) * 2022-11-17 2025-09-24 ERX Pharmaceuticals Inc. Celastrol salts, crystalline forms, and uses thereof
WO2025106760A1 (en) * 2023-11-16 2025-05-22 Erx Pharmaceuticals Corporation Intranasal formulations of celastrol
CN119431489A (zh) * 2024-11-13 2025-02-14 肇源县总医院 一种雷公藤红素衍生物及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
FR2875913A1 (fr) 2004-09-29 2006-03-31 Sea On Line Sa Systeme d'alerte anti-collision installe a bord d'un vehicule marin et procede d'analyse anti-collision
ES2277568B1 (es) 2005-12-30 2008-04-01 Consejo Superior De Investigaciones Cientificas Derivados de triterpenoquinona y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
US20110263693A1 (en) * 2006-03-31 2011-10-27 Dana-Farber Cancer Institute, Inc. Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
EP2152252A4 (en) * 2006-11-13 2010-06-02 Univ Columbia SELECTIVE PROTEASOMIC INHIBITORS FOR THE TREATMENT OF DIABETES
WO2009026163A1 (en) * 2007-08-17 2009-02-26 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
CA2808359C (en) * 2010-08-23 2019-09-24 Suzhou Neupharma Co., Ltd. Analogs of celasterol and pharmaceutical compositions comprised thereof
JP6478908B2 (ja) * 2012-05-25 2019-03-06 バーグ エルエルシー 熱ショックタンパク質(HSP)90−βを調節することによる代謝症候群の治療方法
AU2013266252B2 (en) * 2012-05-25 2017-07-06 Spm Oil & Gas Inc. Evaluating systems associated with wellheads
RS58010B1 (sr) * 2012-09-27 2019-02-28 Childrens Medical Ct Corp Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu
CA3044998A1 (en) * 2014-03-26 2015-10-01 The Children's Medical Center Corporation Celastrol and derivatives for the treatment of obesity
JP7034078B2 (ja) 2015-10-23 2022-03-11 イーアールエックス ファーマシューティカルズ インコーポレイテッド セラストロールの類似体
EP3563343A4 (en) 2017-01-02 2020-08-19 Gauss Surgical, Inc. SURGICAL ITEM FOLLOW-UP WITH DUAL ELEMENT IMAGING PREDICTION

Also Published As

Publication number Publication date
AU2016342375A1 (en) 2018-05-17
AU2022204238A1 (en) 2022-07-07
AU2022204238B2 (en) 2023-12-14
AU2016342375B2 (en) 2022-03-17
JP7339992B2 (ja) 2023-09-06
EP3364956A4 (en) 2019-05-01
WO2017070615A1 (en) 2017-04-27
US11753436B2 (en) 2023-09-12
JP2023164877A (ja) 2023-11-14
US20180362575A1 (en) 2018-12-20
CN119241632A (zh) 2025-01-03
JP2018531289A (ja) 2018-10-25
JP7034078B2 (ja) 2022-03-11
CN108601751A (zh) 2018-09-28
RU2018118633A3 (enExample) 2020-02-17
AU2024201504A1 (en) 2024-03-28
BR112018008103A2 (pt) 2018-11-06
JP2022017473A (ja) 2022-01-25
EP3364956A1 (en) 2018-08-29
US20240190911A1 (en) 2024-06-13
US10662218B2 (en) 2020-05-26
US20210061851A1 (en) 2021-03-04
CA3002924A1 (en) 2017-04-27
RU2018118633A (ru) 2019-11-25

Similar Documents

Publication Publication Date Title
MA45430A (fr) Analogues de célastrol
EP3360001A4 (en) HEAD-MOUNTED DISPLAY DEVICE
DK3283625T3 (da) Nukleasemedieret genomeditering
EP3286361A4 (en) Cancer neoepitopes
DK3331869T3 (da) Muscarinagonister
DK3331528T3 (da) Muskarinagonister
DK3277719T3 (da) Polypeptider
EP3316375A4 (en) Redox flow cell
DK3360890T3 (da) Genterapi
DK3331529T3 (da) Muskarinagonister
EP3395868A4 (en) STRUCTURE
DK3310450T3 (da) Olie-vand-separator
EP3337164A4 (en) HEAD-MOUNTED DISPLAY
DK3394281T3 (da) Gærcelle
DK3270930T3 (da) Præeklampsi
EP3381654A4 (en) Liquid blow molding method
EP3393959A4 (en) GRAB
EP3343603A4 (en) STRUCTURE
EP3363322A4 (en) Hair extender
DK3292136T3 (da) Penicillin-g-acylaser
DK3274482T3 (da) Stenborsknop
EP3390373C0 (en) DOTA SUMMARY
EP3548009A4 (en) POLYMERIC NANOPARTICLES
HUE054584T2 (hu) Maropitant készítmény
EP3377179A4 (en) DEUTERED EPI-743